

**AMENDMENTS TO THE SPECIFICATION**

Please replace the Sequence Listing submitted on August 10, 2004 with the Substitute Sequence Listing attached hereto.

At page 2, please delete in its entirety the paragraph beginning at line 17.

Please amend the paragraph beginning at page 7, line 21 as follows:

The invention also provide RANTES variants obtainable by the methods of the invention and having the general formula ~~\*S&#SSQ&&& RANTES(10-68)-AA1SPAA2SSQAA3, AA3, AA3 (SEQ ID NO: 40)~~, in which:

- \* AA1 L or an aromatic residue,
- # AA2 is L, M or V,
- & AA3 is S, P, T or A.

Please amend the paragraph beginning at page 7, line 27, as follows:

Herein, RANTES (10-68) means amino-acids 10 to 68 of the RANTES (an acronym for Regulation upon Activation, Normal T-Expressed and presumably Secreted) chemokine described in the NCBi's database quoted above as listed below.

SPYSSDTTPCCFAYIARPLPRAHIKEYFYTSGKCSNPAVVFVTRKNRQVCANPEK  
KWVREYINSLEMS (SEQ ID NO :40).

Please amend the paragraph beginning at page 8, line 3 as follows:

In a preferred embodiment, the RANTES variants have a N-terminal amino-acid sequence selected among the following sequences:

LSPVSSQSSA(P<sub>1</sub>) (SEQ ID NO: 1), FSPLSSQSSA (P<sub>2</sub>) (SEQ ID NO: 2), LSPMSSQSPA(SEQ ID NO: 3), WSPLSSQSPA(SEQ ID NO: 4), WSPLSSQSSP(SEQ ID NO: 5), LSPQSSLSSS(SEQ ID NO: 6), ASSGSSQSTS(SEQ ID NO: 7), ISAGSSQSTS(SEQ ID NO: 8), RSPMSSQSSP(SEQ ID NO: 9), YSPSSSLAPA(SEQ ID NO: 10), MSPLSSQASA(SEQ ID NO: 11), ASPMSSQSSS(SEQ ID NO: 12), QSPLSSQAST(SEQ ID NO: 13), QSPLSSTASS(SEQ ID NO: 14), LSPLSSQSAA(SEQ ID NO: 15), GSSSSSQTPA(SEQ ID NO: 16), YSPLSSQSSP(SEQ ID NO: 17), FSSVSSQSSS(SEQ ID NO: 18), or, among the following sequences:

VSTLSSPAST(SEQ ID NO: 30), ASSFSSRAPP(SEQ ID NO: 31), QSSASSSSSA(SEQ ID NO: 32), QSPGSSWSAA(SEQ ID NO: 33), QSPPSSWSSS(SEQ ID NO: 34), QSPLSSFTSS(SEQ ID NO: 35), ASPQSSLPA(SEQ ID NO: 36), LSPVSSQSSA(SEQ ID NO: 1), LSPQSSLSSS(SEQ ID NO: 6).